bioRxiv Science⌕ Search

Biology subjects

Porro, M.

Publications and source records attributed to Porro, M..

2 recordsLinked to original sources

Temporal fingerprints of TMS-evoked potentials across thalamocortical circuits

BackgroundElectroencephalographic (EEG) potentials evoked by transcranial magnetic stimulation (TMS) offer a direct window into cortical dynamics. Yet, a systematic exploration of their morphological features, analogous to sensory-evoked potentials, is lacking, especially for stimulation outside the motor cortex. AimTo obtain region-specific properties of frontal, parietal and occipital networks from the time course of TMS-evoked potentials (TEPs). Materials and MethodsWe implemented and applied an automatic procedure to compute peak-to-peak amplitude, peak latency, and inter-peak interval of TEPs recorded from 40 neurotypical subjects stimulated over left occipital (n=25), parietal (n=25), and frontal (n=25) cortices. ResultsOccipital TEPs showed the largest peak-to-peak amplitude and longest latency of the first waveform component, independently of stimulation intensity and consistent with the recruitment of a large patch of densely interconnected neurons. Concerning later components, both latency and inter-peak interval systematically decreased along the posterior-to-anterior axis, reflecting progressively faster recurrent dynamics from the alpha-dominated occipital circuitry to the tightly coupled loops between frontal cortex and subcortical structures. Parietal TEPs showed intermediate amplitude and latency measures, consistent with the heterogeneous cytoarchitectonic and connectional organization of the superior parietal cortex. ConclusionsOur findings suggest that TEP morphology is shaped by the distinct properties of the stimulated networks, with early amplitude reflecting the extent of local recruitment and later temporal features tracking the rhythm of recurrent activity. This work offers a mechanistically grounded and practically accessible approach, also released as a Python-based tool, that allows to characterize cortical reactivity across different brain-states and populations.

neuroscience↗

Bedaquiline Amplifies Proteasome Inhibitor Efficacy and Overcomes Resistance in Multiple Myeloma

Proteasome inhibitors (PIs) are cornerstone therapies for multiple myeloma (MM), yet resistance remains a major barrier to durable responses. To identify druggable vulnerabilities that enhance PIs efficacy, we performed a small-molecule chemical screen in the presence of carfilzomib (CFZ). We identified bedaquiline (BDQ), an FDA-approved antimycobacterial agent, as a potent synergistic partner. BDQ and its fumarate salt (BDQ-F) significantly amplified CFZ-induced cytotoxicity in PI-sensitive and PI-resistant MM cells, in AL amyloidosis and other B-cell malignancies, with minimal toxicity toward normal cells. Mechanistic studies confirmed that BDQ specifically targets the ATP5F1C subunit of mitochondrial ATP synthase. BDQ-CFZ combination triggered extensive apoptosis, exacerbating proteotoxic stress and proteasome-associated pathways. BDQ specifically enhanced CFZs inhibition of the proteasomes chymotrypsin-like activity. Importantly, BDQ synergized with multiple proteasome and ubiquitin-activating enzyme inhibitors, but not with other standard MM agents, underscoring its selective interaction with the UPS pathway. BDQ-CFZ co-treatment markedly reduced MM cell viability and tumor burden in patient-derived cells and zebrafish xenograft models. These findings support the therapeutic repurposing of BDQ to potentiate PIs efficacy and overcome resistance in MM and related B-cell malignancies. KEY POINTSO_LIBedaquiline synergizes with proteasome inhibitors in MM and other hematologic malignancies, sparing normal cells C_LIO_LIBedaquiline targets ATP synthase {gamma} and boosts carfilzomib by enhancing chymotrypsin-like proteasome inhibition C_LI NOVELTYWe identify the antimicrobial bedaquiline and its fumarate salt as potent enhancers of proteasome inhibitor efficacy in multiple myeloma and other B-cell malignancies. By inhibiting ATP synthase {gamma}, bedaquiline amplifies chymotrypsin-like proteasome inhibition and overcomes drug resistance. This study reveals a mitochondria- proteasome vulnerability and proposes a clinically actionable strategy to restore sensitivity and reduce toxicity of proteasome-based therapies. VISUAL ABSTRACT O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=135 SRC="FIGDIR/small/661768v1_ufig1.gif" ALT="Figure 1"> View larger version (42K): org.highwire.dtl.DTLVardef@339391org.highwire.dtl.DTLVardef@1d3271org.highwire.dtl.DTLVardef@daa0faorg.highwire.dtl.DTLVardef@17eb4eb_HPS_FORMAT_FIGEXP M_FIG C_FIG

cancer biology↗